MedChemExpress LLC (MCE)
  1. Companies
  2. MedChemExpress LLC (MCE)
  3. Products
  4. MedChemExpress - Model Zalifrelimab - ...

MedChemExpressModel Zalifrelimab - 2148321-69-9

SHARE
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Zalifrelimab

MCE China:Zalifrelimab

Brand:MedChemExpress (MCE)

Cat. No.HY-P99514

CAS:2148321-69-9

Synonyms:AGEN1884

Purity:98.28%

Storage:Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping:Shipping with dry ice.

Description:Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.

In Vitro:Zalifrelimab (AGEN1884; 0.1, 1, 10 or 100 μg/mL) potently enhances antigen-specific T cell responsiveness that could be potentiated in combination with other immunomodulatory antibodies. Zalifrelimab combined effectively with PD-1 blockade to elicit a T cell proliferative response in the periphery[2].

In Vivo:Zalifrelimab (AGEN1884; 10 mg/kg; i.v.; on days 1 and 29) is well-tolerated in non-human primates and enhances vaccine-mediated antigen-specific immunity[2].

Species:Human

Isotype:Human IgG1 kappa

Recommend Isotype Controls:Human IgG1 kappa, Isotype Control

Hot selling product:Epalrestat  | o-Phenanthroline  | Liquiritigenin  | Santacruzamate A  | Catechin  | Stearic acid  | Phosphatidylcholines,soya  | Livmoniplimab  | Fluridone  | Clemastine (fumarate)

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.  [Content Brief]

[2]. Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。